Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Figures corrected afterwards (2023).
Gross margin
€ 0
Profit
Caution€ -7.7 million
▲ 7% vs 2024
Debts
Low€ 1.8 million
▼ 42% vs 2024
AstriVax Therapeutics from Leuven, company number BE0787990881, closed financial year 2025 with a result of € -7.7 million after tax. For that financial year AstriVax Therapeutics recorded a gross margin of € 0 and equity of € 10.7 million. Compared with financial year 2024, the result moved from € -8.2 million to € -7.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 21, 2026.
What happened at AstriVax Therapeutics?
What happened at AstriVax Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Dieter Karl Weinand stepped down as director. NBB
- Jeanne Bolger stepped down as director. NBB
- Participatiemaatschappij Vlaanderen NV stepped down as director. NBB
- OMX EUROPE VENTURE FUND FPCI BO stepped down as director. NBB
- Shelley Margetson stepped down as director. NBB
- Bart Geers stepped down as director. NBB
- Hanxelle BV stepped down as director. NBB
- Evan Castiglia stepped down as director. NBB
In short
From € 6.7 million loss in 2023 to € 7.7 million loss in 2025.
Pays suppliers within 38 days on average.
A new publication or filing at AstriVax Therapeutics? We notify you, reason included.
Follow AstriVax TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind AstriVax Therapeutics is Halina Novak.
Directors
According to the 2025 annual accounts
Halina Novak
Director
since 2024
Participatiemaatschappij Vlaanderen NV
Director · represented by Bart De Taeye
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE +141 more
since 2022 · until 2028
Dieter Karl Weinand
Director
since 2025 · until 2031
OMX EUROPE VENTURE FUND FPCI BO
Director · represented by Eva Van Overmeire
since 2022 · until 2028
Shelley Margetson
Director
since 2022 · until 2028
since 2022 · until 2028
Director · represented by Hanne Callewaert
since 2022 · until 2028
Jeanne Bolger
Director
since 2022 · until 2028
Evan Castiglia
Director
since 2023 · until 2028
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3 box 4
3001 Leuven
Gaston Geenslaan 3
3001 Leuven
Active since 4 July 2022
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics same network
€ -528,262 gross margin · 2025
AUGUSTINE THERAPEUTICS same network
€ -1.7 million gross margin · 2025
+6 more
Details
- Company number
- 0787.990.881
- VAT number
- BE 0787.990.881
- Registered office
- Gaston Geenslaan 3 bus 4, 3001 Leuven
- Names & denominations
- AstriVax Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 4 July 2022
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied